Drugs.com: Effect of cancer treatment on COVID-19 mortality
A UC study sheds light on death rates as they relate to patients with cancer and COVID-19
Cancer patients treated one to three months prior to COVID-19 diagnosis and those treated with chemoimmunotherapy have the highest 30-day mortality, according to a study presented at the annual meeting of the European Society for Medical Oncology, held virtually from Sept. 19 to 21.
Lead author Trisha Wise-Draper, MD, PhD, associate professor of medicine, UC Health oncologist and member of the UC Cancer Center, and colleagues examined outcomes related to systemic cancer treatment within one year of laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection.
Read the full Drugs.com/HealthDay News story.
Featured photo courtesy of the National Cancer Institute.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
CPS student athletes put their skills to the test in Fifth Third...
April 7, 2025
Cincinnati media cover the fourth annual CPS All-Star Showcase event held Sunday, April 6 in Fifth Third Arena. The University of Cincinnati partnered with Cincinnati Public Schools to showcase the talent of student athletes and help assist homeless families in the school district.
ChemoID test leads to better outcomes in platinum-resistant...
April 7, 2025
MSN and MSN UK highlighted results from a new Phase 3 trial published in the journal npj Precision Oncology that found a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for patients with platinum-resistant ovarian cancer.
Study: Platform-predicted treatments improve outcomes for...
April 4, 2025
Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an assessment of cancer stem cell sensitivity to chemotherapy can accurately decide more effective treatments and lead to increased outcomes for patients with platinum-resistant ovarian cancer.